Michele Park

Michele joined NEA in 2021 as an investor on the healthcare team focused on the biopharma space. Prior to NEA, Michele was an investor at life sciences-focused venture capital firm, Clarus Ventures (now Blackstone Life Sciences), where she led the initiative to launch the Clarus Cancer Fund—a novel investment model designed to generate returns and fuel cancer research through donation. Before Clarus, she spent time in biotechnology research analyst roles at Credit Suisse and Piper Jaffray.

Michele received her Ph.D. in Molecular Biology from Weill Cornell Graduate School of Medical Sciences and completed her dissertation at Memorial Sloan-Kettering Cancer Center. She also holds a B.A. in Molecular Biology from Princeton University. Park serves as Co-Chair of the Cancer Prevention and Research Institute of Texas (CPRIT) Product Development Advisory Committee; Board Trustee for the American Friends of the Royal Philharmonic Orchestra (AFRPO); and is a member of the Council of Korean Americans (CKA) and Private Equity Women Investor Network.